Surface functionalization of XXXX nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in @entity5 therapy.

@entity63880 @entity939 @entity10784 @entity5 @entity6108 @entity7050
This work reports the surface functionalization of polymeric @entity7050 nanoparticles by non-covalent insertion of a homo-bifunctional chemical crosslinker, @entity63880 (BS3) for targeted @entity5 therapy. We dissolved BS3 in aqueous solution of @entity939 during formulation of nanoparticles by a modified solid/oil/water emulsion solvent evaporation method. The non-covalent insertion of BS3 was confirmed by Fourier transform infrared (FTIR) spectroscopy. @entity6108 and @entity10784 were used as a model drug and a cell specific target, respectively. Nanoparticles were characterized for particle size, zeta potential and surface morphology. The qualitative assessment of antibody attachment was performed by transmission electron microscopy (TEM) as well as confocal microscopy. The optimized formulation showed antibody attachment of 86%. However, antibody attachment was abolished upon blocking the functional groups of BS3. The availability of functional antibodies was evaluated by the presence of a light chain fraction after gel electrophoresis. We further evaluated the in vitro release kinetics of @entity6108 from antibody coated and uncoated nanoparticles. The release of @entity6108 is enhanced upon antibody attachment and followed an anomalous release pattern. We also observed that the cellular uptake of nanoparticles was significantly higher in @entity10784 positive cells than in negative cells. Therefore, these results demonstrate the potential use of this method for functionalization as well as to deliver chemotherapeutic agents for treating @entity5 .
